StockpollyBeta
Get App
Popularity #365
ALNY · NASDAQ · Biotechnology

Alnylam Pharmaceuticals (ALNY)

Develops and commercializes RNAi medicines led by the AMVUTTRA-centered TTR franchise.

$247.61
vs last close−4.04 (−1.61%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue7514404946605015935947741,2491,0971,1671,291
Cost of revenue848666698610371143197268211298
Gross profit6663544285914154905236311,052829956993
452470472543492596505647684698687761
Research & development253272261294271300265324359372365413
199198211248221295240323322325323348
General & administrative1991982112482212952403233223253230
Other expenses000000003000
Operating income214−116−4349−77−10518−16368132269231
−63−21−20−60−32−89−60−19−12929−47−54
Interest income253030293231292729272728
Interest expense3131353334393940441296982
Other non-operating income32−10−1527−35021−2185−159−220
Income before tax151−138−64−11−109−194−42−35239161222178
Income tax expense30263−1101631−12−25−1613
Net income from continuing operations148−138−66−17−112−84−57−66251186237164
Other adjustments0000000000−310
Net income148−138−66−17−112−84−57−66251186206164
EPS, basic$1.18−$1.10−$0.52−$0.13−$0.87−$0.65−$0.44−$0.51$1.91$1.41$1.55$1.23
EPS, diluted$1.15−$1.10−$0.52−$0.13−$0.87−$0.65−$0.44−$0.51$1.84$1.37$1.51$1.20
Weighted average shares, basic125126126127129129130130131132133133
Weighted average shares, diluted131126126127129129130130137136138138
EBITDA195−93−1537−60−1411119297304304245
Depreciation & amortization131314151414141414141414
EBIT182−106−2822−74−155−35283290291231